Abstract
Adjuvant endocrine therapy and chemotherapy are now being used extensively to treat primary breast cancer and are probably beginning to have an impact on national mortality data in the U.K. ( 1 , 2 ). The main difficulty at present is identifying those patients who may require such treatment.